Bateman and Morris treat individuals at Barnes-Jewish Hospital. ‘We’re grateful for the Alzheimer’s Association’s support for these trials and for the generous support it provides given us throughout the long journey that has resulted in them,’ Morris says. ‘We have been working for years to locate a way to take care of Alzheimer’s disease before patients develop dementia, and it’s very fascinating to be making plans to start the to begin such trials later this year.’ ‘This project gets the potential to dramatically accelerate the pace of treatment and prevention strategies for Alzheimer’s,’ said William Thies, PhD, the Alzheimer’s Association’s chief medical and scientific officer.The other individuals in the trial did not respond to the therapy. ‘Remember, they were patients with very advanced disease that nothing else had been in a position to quit,’ says Morse, a known person in the Duke Comprehensive Malignancy Center and an expert in vaccine design. ‘We think that in this few patients, the vaccine was able to stimulate the body’s defense system to damage significant amounts of cancer cells despite the presence of an army of neutralizing antibodies and regulatory T cells.’ Morse says those that seemed to advantage the most were those who had the tiniest amount of tumor. Because of this, he says his team is planning long term trials that will test the vaccine in people who have cancers which have been removed, but who are risky of recurrence.